See more : Sparinvest INDEX DJSI World KL (SPIDJWKL.CO) Income Statement Analysis – Financial Results
Complete financial analysis of Creative Medical Technology Holdings, Inc. (CELZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Creative Medical Technology Holdings, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Zhejiang Cheng Yi Pharmaceutical Co., Ltd. (603811.SS) Income Statement Analysis – Financial Results
- Fairfax Financial Holdings Limited (FRFHF) Income Statement Analysis – Financial Results
- Tera Probe, Inc. (6627.T) Income Statement Analysis – Financial Results
- Aimia Inc. (AIM-PC.TO) Income Statement Analysis – Financial Results
- Power Integrations, Inc. (POWI) Income Statement Analysis – Financial Results
Creative Medical Technology Holdings, Inc. (CELZ)
About Creative Medical Technology Holdings, Inc.
Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; StemSpine to treat chronic lower back pain; ImmCelz for the treatment of stroke patients; and OvaStem for treatment of female infertility. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.00K | 88.60K | 87.75K | 164.50K | 165.50K | 124.40K | 4.80K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 3.60K | 28.49K | 47.95K | 50.60K | 45.50K | 70.38K | 8.00K | 766.07K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 5.40K | 60.11K | 39.81K | 113.90K | 120.00K | 54.03K | -3.20K | -766.07K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 60.00% | 67.84% | 45.36% | 69.24% | 72.51% | 43.43% | -66.67% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 1.97M | 6.27M | 109.18K | 0.00 | 0.00 | 96.62K | 260.09K | 85.33K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 1.22M | 1.05M | 898.53K | 664.98K | 20.83K | 19.43K | 20.12K | 20.10K | 0.00 | 14.29K | 30.55K | 53.49K | 13.62K | 1.43K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 3.56M | 3.94M | 2.96M | 1.16M | 1.22M | 1.05M | 898.53K | 664.98K | 20.83K | 19.43K | 20.12K | 20.10K | 19.83K | 14.29K | 30.55K | 53.49K | 13.62K | 1.43K |
| Other Expenses | 94.58K | 92.08K | 92.08K | 66.79K | 26.95K | 21.14K | 0.00 | 9.36K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 5.63M | 10.30M | 3.17M | 1.23M | 1.25M | 1.17M | 1.17M | 759.67K | 20.83K | 19.43K | 20.12K | 20.10K | 19.83K | 14.29K | 30.55K | 53.49K | 13.62K | 1.43K |
| Cost & Expenses | 5.63M | 10.33M | 3.21M | 1.28M | 1.30M | 1.24M | 1.18M | 759.67K | 20.83K | 19.43K | 20.12K | 20.10K | 19.83K | 14.29K | 30.55K | 53.49K | 13.62K | 1.43K |
| Interest Income | 333.56K | 100.33K | 4.28M | 1.23M | 1.90M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 469.00 | 2.33K | 1.95K |
| Interest Expense | 0.00 | 0.00 | 4.28M | 1.23M | 1.90M | 1.36M | 377.59K | 6.40K | 9.93K | 8.59K | 7.16K | 5.49K | 4.23K | 2.97K | 1.06K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 94.58K | 92.08K | 92.08K | 66.79K | 26.95K | 21.14K | 15.99K | 9.36K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -5.53M | -10.15M | -3.03M | -1.05M | -1.10M | -1.09M | -1.16M | -750.32K | -20.83K | -19.43K | -20.12K | -20.10K | -19.83K | -14.29K | -30.55K | -53.49K | -13.62K | -1.43K |
| EBITDA Ratio | -61,394.98% | -11,345.33% | -3,457.24% | -637.11% | -666.60% | -878.68% | -24,204.40% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -5.62M | -10.24M | -3.13M | -1.11M | -1.13M | -1.11M | -1.18M | -766.07K | -20.83K | -19.43K | -20.12K | -20.10K | -19.83K | -14.29K | -30.55K | -53.49K | -13.62K | -1.43K |
| Operating Income Ratio | -62,445.91% | -11,562.50% | -3,562.17% | -677.71% | -682.88% | -895.68% | -24,537.63% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 333.56K | 100.33K | 22.34M | -35.21M | -7.35M | -12.54M | -1.48M | -6.40K | -9.93K | -8.59K | -7.16K | -5.49K | -4.23K | -2.97K | -1.06K | 2.22K | 2.33K | 1.95K |
| Income Before Tax | -5.29M | -10.14M | 19.21M | -36.33M | -8.48M | -13.66M | -2.66M | -766.07K | -30.76K | -28.01K | -27.28K | -25.59K | -24.06K | -17.26K | -31.61K | -51.27K | -11.29K | 523.00 |
| Income Before Tax Ratio | -58,739.71% | -11,449.26% | 21,892.75% | -22,082.21% | -5,126.09% | -10,977.21% | -55,398.08% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -100.33K | 4.28M | 1.23M | 1.90M | -11.18M | 377.59K | 12.80K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.36K | -661.00 | 162.00 |
| Net Income | -5.29M | -10.04M | 14.93M | -37.55M | -10.38M | -13.66M | -2.66M | -766.07K | -30.76K | -28.01K | -27.28K | -25.59K | -24.06K | -17.26K | -31.61K | -52.64K | -9.54K | 1.37K |
| Net Income Ratio | -58,739.71% | -11,336.02% | 17,017.27% | -22,829.68% | -6,271.42% | -10,977.21% | -55,398.08% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.76 | -9.19 | 57.32 | -648.10 | -5.02K | -11.35K | -17.38K | -5.47K | -1.28K | -1.17K | -1.14K | -1.07K | -1.00K | -719.00 | -1.32K | -2.19K | -397.67 | 57.17 |
| EPS Diluted | -3.76 | -9.19 | 45.97 | -648.10 | -5.02K | -11.35K | -17.38K | -5.47K | -1.28K | -1.17K | -1.14K | -1.07K | -1.00K | -719.00 | -1.32K | -2.19K | -397.67 | 57.17 |
| Weighted Avg Shares Out | 1.41M | 1.09M | 260.51K | 57.95K | 2.07K | 1.20K | 153.00 | 140.00 | 24.00 | 24.00 | 24.00 | 24.00 | 24.00 | 24.00 | 24.00 | 24.00 | 24.00 | 24.00 |
| Weighted Avg Shares Out (Dil) | 1.41M | 1.09M | 324.86K | 57.95K | 2.07K | 1.20K | 153.00 | 140.00 | 24.00 | 24.00 | 24.00 | 24.00 | 24.00 | 24.00 | 24.00 | 24.00 | 24.00 | 24.00 |
Creative Medical Technology Holdings Provides Corporate Update
Continuing to Advance Regenerative Therapies for Diabetes and Chronic Lower Back Pain Strong Financial Position with No Long-Term Debt PHOENIX , Nov. 15, 2023 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a...
Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ ("CELZ-201-DDT") Novel Cell Therapy to Treat Chronic Lower Back Pain
Company reaches next clinical trial milestone for the intramuscular treatment of Chronic Lower Back Pain with the first novel allogenic cellular therapy in the United States PHOENIX , Oct. 10, 2023 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. ("Creative Medical...
What Makes Creative Medical Technology Holdings, Inc. (CELZ) a New Buy Stock
Creative Medical Technology Holdings, Inc. (CELZ) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Creative Medical Technology Holdings Receives FDA Clearance to Initiate a Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ (CELZ-201-DDT) for the Treatment of Chronic Lower Back Pain
PHOENIX , Sept. 19, 2023 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, gynecology, and orthopedics, today announced that the U.S....
What Is Allogeneic Cell Therapy, And What's Driving This Market's 25%+ Annual Global Growth?
PHOENIX, AZ / ACCESSWIRE / August 24, 2023 / Biotechnology company Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) seems to be witnessing success in the allogeneic cell therapy market. In Q4 2022, the company - best known for its regenerative approach...
The Immunotherapy Market is Expected to Surpass $351.56 Billion by 2030 - Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) is Contributing to this Growth
PHOENIX, AZ / ACCESSWIRE / July 14, 2023 / Immunotherapy, in general, is an exciting and growing sector in the pharmaceutical industry. It involves manipulating the human body's immune system to treat various diseases.
Creative Medical Technology Reports Advancements In Regenerative Medicine And Improvements In Financial Position In Corporate Update
PHOENIX, AZ / ACCESSWIRE / July 13, 2023 / Creative Medical Technology Holdings, Inc. ("Creative Medical Technology") (NASDAQ:CELZ) recently released an update on their drug pipeline and financial standing going into Q3 2023. The biotechnology company is known for its...
Creative Medical (CELZ) Up 86% on Upbeat Diabetes Study Data
Creative Medical Technology (CELZ) reports positive one-year follow-up data from a study showing the efficacy of CELZ-001 in treating type II diabetes without any serious adverse effects.
3 Methods for Finding Penny Stocks to Buy and Hold
Use these strategies for making money with penny stocks in 2023 The post 3 Methods for Finding Penny Stocks to Buy and Hold appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Creative Medical Technology Holdings Engages Highly Respected International CRO for Phase 1 / 2 Clinical Trial to Treat Type 1 Diabetes Using CELZ-201
PHOENIX--(BUSINESS WIRE)--Creative Medical Technology Holdings, Inc.
Source: https://incomestatements.info
Category: Stock Reports